<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00875368</url>
  </required_header>
  <id_info>
    <org_study_id>08-283</org_study_id>
    <nct_id>NCT00875368</nct_id>
  </id_info>
  <brief_title>Maraviroc Immune Recovery Study</brief_title>
  <acronym>MIRS</acronym>
  <official_title>Maraviroc Immune Recovery Study, A Multicenter, Randomized, Placebo-controlled, Exploratory Mechanistic Study Into the Role of Maraviroc on Immune Recovery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>S.F.L. van Lelyveld</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Onze Lieve Vrouwe Gasthuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Slotervaart Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rijnstate Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Improving cellular immunity by means of increasing CD4 cells is one of the goals
      of antiretroviral therapy in HIV, which is achieved by means of virological suppression. A
      certain group of patients, the so called &quot;immunologic non responders&quot;, fail to reach an
      acceptable CD4 cell increase despite an adequate virologic response on antiretroviral
      treatment. Recently a new antiretroviral agent, maraviroc (Celsentry®), is registered for the
      treatment of patients infected with CCR5 tropic HIV-1 virus. However, data is available
      suggesting that treatment with maraviroc leads to immune recovery (increase in CD4 cells) in
      patients who are infected with dual/mixed tropic HIV-1 virus, in the absence of a virologic
      response. This suggests an alternative mechanism for immune recovery, which could be
      especially beneficial for this group of patients.

      Hypothesis: Maraviroc, by a yet unknown mechanism, stimulates immune recovery by increasing
      CD4+ cell count.

      Objective: The primary objective is to confirm the hypothesis that maraviroc stimulates
      immune recovery; the secondary objective is to explore, by virologic and immunologic
      investigations, the underlying mechanisms of this hypothesis.

      Study design: multicentre, randomized, placebo-controlled, double blind, exploratory
      mechanistic study.

      Study population: HIV-1 infected patients 18 years or older, who meet the inclusion criteria.

      Intervention: One group receives maraviroc (dose dependent on co-medication), the other group
      placebo.

      Main study parameters/endpoints: A 30% increase in CD4 cell rise in the treatment group
      (compared with placebo).

      Nature and extent of the burden and risks associated with participation, benefit and group
      relatedness:

        1. In the treatment group subjects will start with a registered antiretroviral agent
           (maraviroc).

        2. During the treatment year patients will perform several study visits, probably three
           more compared with regular visits on the outpatient clinic.

        3. Each visit, blood will be drawn by venepuncture for immunologic and virologic
           investigations (see flow chart).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>30% increase in CD4+ cell count after 48 weeks</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Maraviroc</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>maraviroc</intervention_name>
    <description>maraviroc dose dependent on co-medication</description>
    <arm_group_label>Maraviroc</arm_group_label>
    <other_name>Celsentri</other_name>
    <other_name>Celsentry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo drug</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  HAART with a maximal treatment interruption of two weeks

          -  viral suppression (&lt; 50 copies/ml) for 6 months

          -  And either:

               -  CD4+ count &lt; 200 cells/microliter after minimal one year of treatment with HAART
                  (study group one) OR

               -  a CD4+ cell count between 200 and 350 cells/microliter after minimal two years of
                  treatment with HAART (study group two)

        Exclusion Criteria:

          -  HAART consisting of a combination of tenofovir and didanosine

          -  Active infection for which antimicrobial treatment

          -  Acute hepatitis B or C

          -  Chronic hepatitis B or C for which treatment with (peg)interferon and/or ribavirin
             (Note: patients with untreated chronic hepatitis B or C can be included)

          -  Immunosuppressive medication

          -  Radiotherapy or chemotherapy in the past 2 years

          -  Pregnancy or breastfeeding an infant

          -  Subjects with known hypersensitivity to maraviroc or to peanuts, or any of its
             excipients or dyes as follows:

               -  Excipients from tablet: microcrystalline cellulose, dibasic calcium phosphate
                  (anhydrous), sodium starch glycolate, magnesium stearate.

               -  Film-coat: [Opadry II Blue (85G20583) contains FD&amp;C blue #2 aluminium lake, soya
                  lecithin, polyethylene glycol (macrogol 3350), polyvinyl alcohol, talc and
                  titanium dioxide.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andy IM Hoepelman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1091 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum (AMC)</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slotervaartziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kennemer Gasthuis</name>
      <address>
        <city>Haarlem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum (LUMC)</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015GJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maasstad Ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint Elisabeth Ziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ùniversity Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2009</study_first_submitted>
  <study_first_submitted_qc>April 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2009</study_first_posted>
  <last_update_submitted>September 6, 2013</last_update_submitted>
  <last_update_submitted_qc>September 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>S.F.L. van Lelyveld</investigator_full_name>
    <investigator_title>Coordinating investigator</investigator_title>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <keyword>HAART</keyword>
  <keyword>CD4 cell</keyword>
  <keyword>Immunologic non-responders</keyword>
  <keyword>Immunology</keyword>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

